The article A Deeper Look at atai Life Sciences’ Company Update was originally published on Microdose. atai Life Science has released its most recent...
The article Reunion Neuroscience Completes Data Analysis for Phase 1 Clinical Trial was originally published on Microdose. Reunion Neuroscience Completes...
It seems it is business as usual for Mind Medicine, aka MindMed, (NASDAQ: MNMD) as the firm gave updates on The post MindMed Expects Results For...
The article Secretive GH Research Provides Business Updates and Upcoming Milestones was originally published on Microdose. Secretive psychedelic drug...
Reunion will present findings to the FDA. The post Postpartum Depression Psychedelic Treatment Studied In Reunion’s Phase 1 Trial appeared first on Green...
Nintendo World is coming to the US for theme park guests looking to level up their vacation experience.
Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced the distribution...
The article Atai Announces Disappointing Results in PCN-101 Phase 2a Trial was originally published on Microdose. The industry has been waiting for these...
During this edition of the Investor Hotseat, host Dustin Robinson of Iter Investments is joined by Tom McDonald of Clerkenwell Health. Clerkenwell Health...
Atai plans to continue working with its compound despite the setback. The post Atai Life Sciences Ketamine Treatment for Depression Fails in Mid-Stage...